Oncotarget

Corrections:

Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

PDF  |  How to cite

Oncotarget. 2018; 9:35283-35283. https://doi.org/10.18632/oncotarget.26252

Metrics: PDF 957 views  |   ?  

Zexi Hu1,2,*, Yong Hu1,2,*, Xicheng Liu2, Rongwen Xi2, Aiqun Zhang3, Deruo Liu4, Qiang Xie5 and Liang Chen2,6

1 College of Life Sciences, Beijing Normal University, Beijing, China
2 National Institute of Biological Sciences, Beijing, China
3 The General Hospital of People’s Liberation Army (301 hospital), Beijing, China
4 Department of thoracic surgery, China-Japan Friendship Hospital, Beijing, China
5 Fuzhou Pulmonary Hospital of Fujian, Fujian, China
6 National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, China
* Co-first author

Published: October 16, 2018

This article has been corrected: The correct Acknowledgment information is given below:

ACKNOWLEDGMENTS

This work was funded by National Natural Science Foundation of China grant 81472606, Chinese Ministry of Science and Technology grant (973 grant) 2011CB812401, and the Beijing Municipal Government.

Original article: Oncotarget. 2015; 6:31628-31639. DOI: https://doi.org/10.18632/oncotarget.5221.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26252